# A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05221840/  
OnCo record `nct05221840` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Oleclumab in non-small-cell lung cancer, active and no longer recruiting.

## Summary

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT05221840, led by AstraZeneca, and active but no longer recruiting on the registry. Official title: A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy. Planned enrolment is 1051 participants (actual). The study started in 2022-02-07 and primary completion is expected in 2026-09-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: PACIFIC-9
- Tags: ctgov-ingest
- Registry id: NCT05221840
- Phase: 3
- Setting: A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
- Sponsor: AstraZeneca
- Enrolled: 1051

## Sources

- ClinicalTrials.gov NCT05221840: https://clinicaltrials.gov/study/NCT05221840

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Unresectable stage III non-small-cell lung cancer](https://onco.cc/cancers/stage-iii-unresectable-nsclc/)
- drugs: [Monalizumab](https://onco.cc/drugs/monalizumab/), [Oleclumab](https://onco.cc/drugs/oleclumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05221840.json